Cost-Effectiveness Analysis in Healthcare

Learning Objectives

By the end of this chapter, you should be able to:

• Define cost-effectiveness analysis (CEA) and identify its five key components.
• Calculate and interpret a cost-effectiveness ratio (CER) and an incremental cost-effectiveness ratio (ICER).
• Explain how CEA differs from cost-benefit and cost-utility analysis.
• Apply CEA reasoning to a medication therapy management (MTM) case study.
• Evaluate the limitations of CEA and identify when it is not the most appropriate analytic tool.

Quick Answer

Cost-effectiveness analysis (CEA) is a method for comparing the cost of a healthcare intervention to the health outcome it produces, so decision-makers can judge whether it delivers good value relative to an alternative. In pharmacy, CEA is the workhorse tool for deciding which of two or more treatments for the same condition offers the best health return per rupee or dollar spent — for example, comparing two antihypertensives on cost per mmHg of blood pressure reduction. It matters because healthcare resources are limited and payers, hospitals, and health systems need a consistent, quantitative way to prioritize spending rather than relying on price alone or on manufacturer claims.

What Is Cost-Effectiveness Analysis?

Cost-effectiveness analysis compares the costs of different interventions or treatments to their outcomes, expressed in natural clinical units. It aims to identify the most effective way to achieve a desired health outcome within available resources. In pharmacy, CEA is commonly used to evaluate new drugs, treatment protocols, or clinical programs against a comparator, usually current standard care.

Every CEA has five essential components:

• Intervention: The treatment or program being evaluated (e.g., a new drug)
• Comparator: The alternative being measured against, usually the current standard of care
• Outcome measure: The health benefit achieved, expressed in natural clinical units (e.g., mmHg reduced, infections prevented) — note that when the outcome is a QALY instead, the analysis becomes a cost-utility analysis rather than a CEA
• Resource use: The costs associated with both the intervention and the comparator (drug cost, monitoring, administration, adverse-event management)
• Time horizon: The period over which costs and effects are measured — short time horizons can understate long-term benefits or costs

How CEA Works: The Core Calculation

The simplest output of a CEA is the cost-effectiveness ratio (CER):

CER = Total cost of intervention ÷ Total effect of intervention

But comparing two CERs in isolation can be misleading. The more decision-relevant number is the incremental cost-effectiveness ratio (ICER), which asks: for the extra money spent on the more effective option, how much extra benefit do you get?

ICER = (Cost of new intervention − Cost of comparator) ÷ (Effect of new intervention − Effect of comparator)

A low ICER means you're getting a lot of extra benefit for a small extra cost — generally attractive. A high ICER means the extra benefit is expensive to buy — decision-makers must judge whether it's still worth it, often against a pre-defined "willingness-to-pay" threshold per unit of outcome (or per QALY, when using cost-utility analysis).

Worked Example: Medication Therapy Management for Diabetes

Consider a hospital evaluating whether to invest in a comprehensive Medication Therapy Management (MTM) program for diabetic patients, compared to standard pharmacist care:

• Intervention: Comprehensive MTM program (medication review, dose optimization, lifestyle counseling) — cost: ₹6,000 per patient over 6 months
• Comparator: Standard care (usual brief pharmacist interaction) — cost: ₹2,000 per patient over 6 months
• Outcome measure: Reduction in HbA1c after 6 months — MTM: 1.5 percentage points; Standard care: 0.9 percentage points
• Time horizon: 6 months

Step 1 — Calculate the CER for each option:

• MTM: ₹6,000 ÷ 1.5 = ₹4,000 per percentage-point HbA1c reduction
• Standard care: ₹2,000 ÷ 0.9 = ₹2,222 per percentage-point HbA1c reduction

Step 2 — Calculate the ICER (the decision-relevant number):

ICER = (₹6,000 − ₹2,000) ÷ (1.5 − 0.9) = ₹4,000 ÷ 0.6 = ₹6,667 per additional percentage-point HbA1c reduction

Step 3 — Interpret: The MTM program costs an extra ₹6,667 for every additional percentage point of HbA1c reduction beyond what standard care achieves. Whether that's "worth it" depends on whether the hospital's implicit or explicit willingness-to-pay threshold for glycemic control exceeds ₹6,667 per point — and on secondary considerations like whether better HbA1c control now prevents costlier complications (kidney disease, amputations, cardiovascular events) later, which a longer time horizon would capture but this 6-month analysis does not.

Pharmacoeconomics and Outcomes Research: How They Connect to CEA

Pharmacoeconomics is the broader study of the economic implications of pharmaceutical products; outcomes research is the discipline that measures the impact of interventions on patient outcomes (see Chapter 2). CEA sits at the intersection of the two — it is the analytic method that takes outcomes-research data (the effect) and pharmacoeconomic data (the cost) and combines them into a single, comparable ratio.

• Economic evaluations like CEA inform policy decisions regarding drug approval, formulary placement, and reimbursement.
• Outcome measures generated by outcomes research provide the "effect" half of every CEA calculation — without reliable outcomes data, a CEA cannot be performed.
• Both fields together answer the question that neither can answer alone: is this pharmaceutical intervention worth its cost, given the health it actually delivers?

Applications in Pharmacy Practice

• Formulary management: Deciding which medications should be covered by a hospital or insurance plan, often using an ICER threshold as a formal criterion.
• Drug selection: Helping pharmacists and prescribers choose the most cost-effective medication for a given patient or population.
• Clinical trials: Embedding economic evaluation alongside efficacy endpoints during drug development, to prepare pricing and reimbursement dossiers.
• Healthcare policy: Informing national and institutional decisions about resource allocation, such as which vaccines or screening programs to fund.

Key Terms

Term	Definition
Cost-effectiveness analysis (CEA)	Economic evaluation comparing the cost of interventions to their outcomes, measured in natural clinical units
Intervention	The treatment or program being evaluated in an economic analysis
Comparator	The alternative (often standard of care) against which the intervention is measured
Outcome measure	The health benefit achieved by an intervention, used as the denominator in a CER
Resource use	The costs consumed by an intervention and its comparator, including direct and indirect costs
Time horizon	The period over which costs and effects of an intervention are measured and compared
Cost-effectiveness ratio (CER)	Total cost of an intervention divided by its total effect
Incremental cost-effectiveness ratio (ICER)	The extra cost of one intervention over another divided by its extra benefit
Willingness-to-pay threshold	The maximum amount a payer or health system is prepared to pay per unit of outcome (or per QALY)
Medication Therapy Management (MTM)	A structured pharmacist-led service to optimize a patient's drug therapy, review adherence, and reduce adverse events

Common Mistakes

Misconception 1: "A lower CER always means the better choice." Why it's wrong: Comparing two CERs in isolation ignores how much extra benefit or cost separates the options — a slightly higher CER intervention might still be worth adopting if it delivers substantially more benefit overall. Correct understanding: Decision-makers should calculate the ICER to see what the extra cost buys in extra benefit, rather than judging CERs side by side without context.

Misconception 2: "CEA and cost-benefit analysis (CBA) are interchangeable terms." Why it's wrong: CEA measures outcomes in natural clinical units (e.g., mmHg, infections avoided), which restricts comparisons to interventions treating the same condition. CBA converts outcomes into monetary terms, which allows comparison across completely different types of programs. Correct understanding: Use CEA to compare treatments within the same disease area; use CBA (or cost-utility analysis with QALYs) when comparing across different disease areas or sectors.

Misconception 3: "A short time horizon is always sufficient because it captures the main cost and outcome data." Why it's wrong: Many drug therapies (e.g., for diabetes, hypertension) produce benefits — like avoided complications — that only appear years after treatment begins; a 6-month or 1-year horizon can badly understate true value. Correct understanding: The time horizon should match the natural history of the disease; chronic conditions typically need extrapolated, longer-term models (using health economic modeling techniques) to capture the full cost-effectiveness picture.

Comparison and Connections

Feature	Cost-effectiveness analysis (CEA)	Cost-benefit analysis (CBA)	Cost-utility analysis (CUA)
Outcome unit	Natural clinical unit (mmHg, infections avoided)	Monetary value	QALYs
Cross-disease comparison?	No — limited to same condition/outcome	Yes	Yes
Typical use in pharmacy	Comparing two drugs for the same condition	Comparing a health program to a non-health investment	National reimbursement/HTA decisions
Key output	CER / ICER (₹ per clinical unit)	Net monetary benefit	ICER (₹ per QALY)

Practice Questions

Recall

1. List the five key components of a cost-effectiveness analysis. Answer guidance: Intervention, comparator, outcome measure, resource use, and time horizon.
2. Write the formula for the incremental cost-effectiveness ratio (ICER). Answer guidance: ICER = (Cost of new intervention − Cost of comparator) ÷ (Effect of new intervention − Effect of comparator).

Understanding

3. Explain why the ICER is generally more useful for decision-making than comparing two CERs directly. Answer guidance: The ICER isolates the extra cost required to achieve the extra benefit of the more effective option, which is the actual trade-off decision-makers face, whereas standalone CERs can look similar while hiding very different marginal trade-offs.
4. Why can't CEA be used to compare a diabetes drug against a mental health program? Answer guidance: CEA measures outcomes in disease-specific natural units (e.g., HbA1c reduction vs. depression score change), which are not comparable across different conditions; a common unit like QALYs (cost-utility analysis) or money (cost-benefit analysis) is required for cross-disease comparisons.

Application

5. Drug X costs ₹500/month and reduces LDL cholesterol by 20 mg/dL. Drug Y costs ₹800/month and reduces LDL by 35 mg/dL. Calculate the ICER for Drug Y relative to Drug X. Answer guidance: ICER = (800−500)/(35−20) = ₹300/15 = ₹20 per additional mg/dL LDL reduction.
6. A hospital's MTM program shows an ICER of ₹6,667 per additional percentage-point HbA1c reduction over standard care (see the worked example above). What additional information would you want before recommending adoption? Answer guidance: Whether the hospital's willingness-to-pay threshold for glycemic improvement exceeds this figure; whether a longer time horizon would reveal downstream savings from avoided complications; and practical factors like staffing capacity to deliver the MTM program.

Analysis

7. A new drug has a lower CER than the standard treatment but is also far less effective in absolute terms (e.g., cheap but barely works). Critically evaluate whether this drug should be adopted based on CEA alone. Answer guidance: A low CER driven mainly by low cost rather than high effectiveness can be misleading; absolute effectiveness matters clinically, and a drug that is "cost-effective" but clinically inadequate may not meet minimum efficacy standards. CEA should be interpreted alongside clinical significance thresholds, not the ratio alone.
8. Compare how a 6-month time horizon versus a 10-year time horizon would change the conclusions of the MTM cost-effectiveness example in this chapter. What kind of analytic tool would be needed to extend the time horizon appropriately? Answer guidance: A 6-month horizon only captures direct HbA1c improvement and program cost; a 10-year horizon would need to project downstream effects like reduced diabetic complications (nephropathy, retinopathy, amputations) and their associated cost savings. This requires a health economic model (e.g., a Markov model) rather than a simple trial-period CEA, since it must extrapolate beyond directly observed data.

FAQ

How is CEA different from a simple cost comparison? A simple cost comparison only looks at price. CEA relates price to outcome, so it can reveal that a more expensive option is actually better value if its extra benefit outweighs its extra cost.

What counts as an acceptable ICER? There's no universal number — it depends on the health system's willingness-to-pay threshold, which varies by country and by how the outcome is measured. Some countries publish explicit thresholds (often expressed as cost per QALY) that agencies use as reference points, while for CEAs measured in natural units, the threshold is usually judged case by case.

Can CEA be used for non-drug interventions like screening programs or pharmacist services? Yes. CEA applies to any healthcare intervention with a measurable cost and outcome — screening programs, vaccination campaigns, and pharmacist-led services like MTM are all commonly evaluated this way.

Why do time horizon choices matter so much in CEA? Because costs and benefits of chronic disease treatments often play out over years, not months. A short time horizon can miss delayed benefits (like fewer complications) or delayed costs (like long-term side effects), skewing the ratio in either direction.

Is a negative ICER good or bad? It depends on the quadrant. If the new intervention is both cheaper and more effective (dominant), the ICER is negative and the intervention is a clear win. If it's more expensive and less effective (dominated), a negative ICER signals it should be rejected. Always check both cost and effect direction, not just the sign of the ratio.

Quick Revision

• CEA compares intervention costs to outcomes measured in natural clinical units (not money, not QALYs).
• Five CEA components: intervention, comparator, outcome measure, resource use, time horizon.
• CER = total cost ÷ total effect.
• ICER = (cost difference) ÷ (effect difference) — the key number for comparing two options.
• A low ICER = good value (small extra cost for large extra benefit); a high ICER = poor value.
• CEA cannot compare across different diseases — use cost-utility analysis (QALYs) or cost-benefit analysis (money) for that.
• Time horizon must match the disease's natural history; short horizons can understate long-term benefits of chronic disease treatment.
• Outcomes research supplies the "effect" data; pharmacoeconomics supplies the "cost" framework — CEA combines both.
• Applications include formulary management, drug selection, clinical trial economic sub-studies, and healthcare policy.
• A "dominant" intervention (cheaper and more effective) is an easy adopt decision; a "dominated" one (costlier and less effective) should be rejected.
• The willingness-to-pay threshold is the benchmark against which an ICER is judged acceptable or not.

Related Topics

Prerequisites: Introduction to Pharmacoeconomics (Chapter 1), Health Outcomes Assessment (Chapter 2), basic arithmetic/ratio calculations.

Related Topics: Cost-utility analysis and QALYs, cost-benefit analysis, health technology assessment, budget impact analysis.

Next Topics: Health economic modeling (Markov models, decision trees), formulary and reimbursement decision-making, and pharmacoeconomic evaluation in clinical trial design.